Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.

This study has been completed.
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: September 18, 2007
Last updated: November 3, 2014
Last verified: November 2014

This single arm study will assess the safety and effect on response rate of a co mbination of MabThera and chlorambucil in previously untreated patients with B-c ell chronic lymphocytic leukemia. Patients will receive 6x monthly cycles of com bination treatment, followed by up to 6 cycles of chlorambucil alone. MabThera w ill be administered on day 1 of each cycle, at a dose of 375mg/m2 iv in cycle 1, and 500mg/m2 in subsequent cycles, and chlorambucil will be administered on day s 1-7 of each cycle at a dose of 10mg/m2/day po. The anticipated time on study t reatment is 3-12 months, and the target sample size is <100 individuals.

Condition Intervention Phase
Lymphocytic Leukemia, Chronic
Drug: rituximab [MabThera/Rituxan]
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label Study to Characterize the Safety and Response Rate of MabThera (Rituximab) Plus Chlorambucil in Previously Untreated Patients With CD20-positive B-cell Chronic Lymphocytic Leukemia

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • AE profile; laboratory parameters [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Tumor response rate, PFS, DFS, duration of response, overall survival, molecular remission. [ Time Frame: Event driven ] [ Designated as safety issue: No ]

Enrollment: 100
Study Start Date: October 2007
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: rituximab [MabThera/Rituxan]
375mg/m2 iv on day 1 of cycle 1; 500mg/m2 on day 1 of cycles 2-6


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia;
  • patients with progressive Binet stage B, or C requiring therapy according to NCI criteria;
  • ECOG performance status <=2.

Exclusion Criteria:

  • previous treatment for CLL;
  • known concomitant hematological malignancy;
  • transformation to aggressive B-cell malignancy;
  • history of severe cardiac disease;
  • known hypersensitivity or anaphylactic reactions to murine antibodies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00532129

United Kingdom
Birmingham, United Kingdom, B9 5SS
Bournemouth, United Kingdom, BH7 7DW
Cambridge, United Kingdom, CB2 0QQ
Canterbury, United Kingdom, CT1 3NE
Cottingham, United Kingdom, HU16 5JQ
Leeds, United Kingdom, LS9 7TF
Leicester, United Kingdom, LE1 5WW
Liverpool, United Kingdom, L7 8XP
London, United Kingdom, NW1 2PG
London, United Kingdom, EC1M 6BQ
Sutton, United Kingdom, SM2 5PT
Wakefield, United Kingdom, WF1 4DG
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided by Hoffmann-La Roche

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche Identifier: NCT00532129     History of Changes
Other Study ID Numbers: MO20927
Study First Received: September 18, 2007
Last Updated: November 3, 2014
Health Authority: England: National Patient Safety Agency and Research Ethics Committees

Additional relevant MeSH terms:
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014